Fig. 4

miR-8084 targets the 3′-UTR of ING2. a The putative binding sites of miR-8084 in ING2 3′-UTR region were predicted. The matched seed sequences were indicated by vertical lines. b Schematic graph of the putative binding sites of miR-8084 in the ING2 3′UTR and the mutation in miR-8084 binding sites. c miR-8084 mimics down-regulated luciferase activities controlled by wild-type ING2 3′UTR, but did not affect luciferase activity controlled by mutant ING2 3′UTR. The results are means of three independent experiments ± SD (*P < 0.05). d The Cancer Gemone Atlas online database was queried using cBioportal to analysis ING2 gene alteration in human cancers. e The survival curves was performed by Kaplan–Meier plotter (http://kmplot.com/analysis/; probe ID: 213544_at). Totally, 3951 patients were included, 1977 cases were in ING2 low-expression cohort, and 1974 cases were in ING2 high-expression cohort. The median survival for ING2 high-expression cohort is 228.85 months, and 185.16 months for ING2 low-expression cohort. f Survival analysis for breast cancer using data from TCGA. 1091 patients were included, 546 cases were in ING2 low-expression cohort, and 545 cases were in ING2 high-expression cohort. The median survival for ING2 high-expression cohort is 129.6 months, and 120.53 months for ING2 low-expression cohort. 449 and 478 cases are censored in ING2 low-expression and high-expression cohort respectively. g ING2 participates in the regulation of genes involved in cell proliferation, cell cycle, and apoptosis